Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo

Breast cancer (BC) is the most frequently diagnosed female cancer and second leading cause of death. Despite the discovery of many antineoplastic drugs for BC, the current therapy is not totally efficient. In this study, we investigated the potential of repurposing the well-known diabetes type II dr...

Full description

Bibliographic Details

Published in:	Chemico-biological interactions Vol. 349; p. 109641
Main Authors:	Chequin, Andressa, Costa, Luiz E., de Campos, Felipe F., Moncada, Angie D.B., de Lima, Lucas T.F., Sledz, Lucas R., Picheth, Guilherme F., Adami, Eliana R., Acco, Alexandra, Gonçalves, Marcos B., Manica, Graciele C.M., Valdameri, Gláucio, de Noronha, Lucia, Telles, José E.Q., Jandrey, Elisa H.F., Costa, Erico T., Costa, Fabricio F., de Souza, Emanuel M., Ramos, Edneia A.S., Klassen, Giseli
Format:	Journal Article
Language:	English
Published:	Elsevier B.V 01.11.2021
Subjects:	Breast cancer DNA methylation DNMT1 Drug repurposing Epigenetics Liraglutide Epigenetics DNA methylation Drug repurposing DNMT1 Breast cancer Liraglutide
ISSN:	0009-2797, 1872-7786, 1872-7786
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!